Simultaneous Left Ventricular Volume and Strain Changes During Chemotherapy Associate With 2-Year Postchemotherapy Measures of Left Ventricular Ejection Fraction.
Adult
Aged
Antineoplastic Agents
/ adverse effects
Cardiotoxicity
Female
Heart Disease Risk Factors
Humans
Male
Middle Aged
Neoplasms
/ drug therapy
Prospective Studies
Stroke Volume
/ drug effects
Time Factors
Ventricular Dysfunction, Left
/ chemically induced
Ventricular Function, Left
/ drug effects
cardiotoxicity
chemotherapy
global circumferential strain
left ventricular ejection fraction
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
21 01 2020
21 01 2020
Historique:
entrez:
22
1
2020
pubmed:
22
1
2020
medline:
15
12
2020
Statut:
ppublish
Résumé
Background Although changes in left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume, and global circumferential strain occur during cancer treatment, the relationship of these changes to the 2-year post-cancer-treatment measures of left ventricular ejection fraction (LVEF) are unknown. Methods and Results In a prospective, continuously recruited cohort of 95 patients scheduled to receive potentially cardiotoxic chemotherapy for breast cancer, lymphoma, or soft tissue sarcoma, measures of left ventricular end-diastolic volume, LVESV, global circumferential strain, and LVEF were acquired via cardiac magnetic resonance imaging before and then 3 and 24 months after initiating treatment by individuals blinded to all patient identifiers. Participants had an average age of 54±15 years; 68% were women, and 82% were of white race. LVEF declined from 62±7% to 58±9% over the 24 months (
Identifiants
pubmed: 31959033
doi: 10.1161/JAHA.119.015400
pmc: PMC7033821
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e015400Subventions
Organisme : NHLBI NIH HHS
ID : K01 HL145329
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA167821
Pays : United States
Organisme : NCI NIH HHS
ID : R33 CA091216
Pays : United States
Références
Circ Heart Fail. 2018 Jul;11(7):e004560
pubmed: 29991488
J Cardiovasc Magn Reson. 2017 Aug 2;19(1):59
pubmed: 28768517
J Am Coll Cardiol. 2013 Jan 8;61(1):77-84
pubmed: 23199515
Circulation. 2017 Jun 20;135(25):2575-2577
pubmed: 28630272
J Am Coll Cardiol. 2006 Dec 5;48(11):2285-92
pubmed: 17161261
JACC Heart Fail. 2018 Dec;6(12):1023-1032
pubmed: 30414819
JACC Cardiovasc Imaging. 2013 Aug;6(8):877-85
pubmed: 23643285
Circ Heart Fail. 2017 Feb;10(2):
pubmed: 28209767
J Am Soc Echocardiogr. 2014 Sep;27(9):911-39
pubmed: 25172399
Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603
pubmed: 22744937
Circulation. 2009 Apr 14;119(14):e391-479
pubmed: 19324966
Am Heart J. 1992 Oct;124(4):1017-25
pubmed: 1529875
J Cardiovasc Magn Reson. 2013 Jul 31;15:66
pubmed: 23902649
J Am Heart Assoc. 2020 Jan 21;9(2):e015400
pubmed: 31959033
Curr Oncol Rep. 2016 Aug;18(8):48
pubmed: 27292153
Am J Cardiol. 2017 May 15;119(10):1637-1642
pubmed: 28341361
JACC Cardiovasc Imaging. 2018 Aug;11(8):1150-1172
pubmed: 30092971
J Am Soc Echocardiogr. 2013 May;26(5):493-8
pubmed: 23562088